Diabetes & Metabolism Journal

Original Articles

Clinical Diabetes & Therapeutics
Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea: Yu Mi Kang, Chang Hee Jung, Seung-Hwan Lee, Sang-Wook Kim, Kee-Ho Song, Sin Gon Kim, Jae Hyeon Kim, Young Min Cho, Tae Sun Park, Bon Jeong Ku, Gwanpyo Koh, Dol Mi Kim, Byung-Wan Lee, Joong-Yeol Park; Diabetes Metab J. 2019;43(4):432-446. Published online June 19, 2019; DOI: https://doi.org/10.4093/dmj.2018.0092

6,188 View
98 Download
2 Web of Science
2 Crossref

Abstract PDF Supplementary Material PubReader

Background

We aimed to investigate the effectiveness and safety of adding basal insulin to initiating dipeptidyl peptidase-4 (DPP-4) inhibitor and metformin and/or sulfonylurea (SU) in achieving the target glycosylated hemoglobin (HbA1c) in patients with type 2 diabetes mellitus (T2DM).

Methods

This was a single-arm, multicenter, 24-week, open-label, phase 4 study in patients with inadequately controlled (HbA1c ≥7.5%) T2DM despite the use of DPP-4 inhibitor and metformin. A total of 108 patients received insulin glargine while continuing oral antidiabetic drugs (OADs). The primary efficacy endpoint was the percentage of subjects achieving HbA1c ≤7.0%. Other glycemic profiles were also evaluated, and the safety endpoints were adverse events (AEs) and hypoglycemia.

Results

The median HbA1c at baseline (8.9%; range, 7.5% to 11.1%) decreased to 7.6% (5.5% to 11.7%) at 24 weeks. Overall, 31.7% subjects (n=33) achieved the target HbA1c level of ≤7.0%. The mean differences in body weight and fasting plasma glucose were 1.2±3.4 kg and 56.0±49.8 mg/dL, respectively. Hypoglycemia was reported in 36 subjects (33.3%, 112 episodes), all of which were fully recovered. There was no serious AE attributed to insulin glargine. Body weight change was significantly different between SU users and nonusers (1.5±2.5 kg vs. −0.9±6.0 kg, P=0.011).

Conclusion

The combination add-on therapy of insulin glargine, on metformin and DPP-4 inhibitors with or without SU was safe and efficient in reducing HbA1c levels and thus, is a preferable option in managing T2DM patients exhibiting dysglycemia despite the use of OADs.

Citations

Citations to this article as recorded by

Glycaemic control with add‐on thiazolidinedione or a sodium‐glucose co‐transporter‐2 inhibitor in patients with type 2 diabetes after the failure of an oral triple antidiabetic regimen: A 24‐week, randomized controlled trial
Jaehyun Bae, Ji Hye Huh, Minyoung Lee, Yong‐Ho Lee, Byung‐Wan Lee
Diabetes, Obesity and Metabolism.2021; 23(2): 609. CrossRef
Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
Kyung-Soo Kim, Byung-Wan Lee
Clinical and Molecular Hepatology.2020; 26(4): 430. CrossRef

Clinical Diabetes & Therapeutics
Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials: Yu Mi Kang, Yun Kyung Cho, Jiwoo Lee, Seung Eun Lee, Woo Je Lee, Joong-Yeol Park, Ye-Jee Kim, Chang Hee Jung, Michael A. Nauck; Diabetes Metab J. 2019;43(4):410-421. Published online December 27, 2018; DOI: https://doi.org/10.4093/dmj.2018.0070

7,215 View
150 Download
21 Web of Science
20 Crossref

Abstract PDF Supplementary Material PubReader

Background

Based on reported results of three large cardiovascular outcome trials (CVOTs) of glucagon-like peptide 1 receptor agonists (GLP-1 RAs), we aimed to investigate the overall effect of GLP-1 RAs on major adverse cardiovascular events (MACEs) and to identify subpopulations exhibiting the greatest cardiovascular (CV) benefit.

Methods

Three CVOTs reporting effects of long-acting GLP-1 RAs were included: LEADER (liraglutide), SUSTAIN-6 (semaglutide), and EXSCEL (exenatide once weekly). In all studies, the primary endpoint was three-point MACE, comprising CV death, non-fatal myocardial infarction, and non-fatal stroke. Overall effect estimates were calculated as hazard ratios and 95% confidence intervals (CIs) using the random-effects model; subgroup analyses reported in the original studies were similarly analyzed.

Results

Overall, statistically significant risk reductions in MACE and CV death were observed. Subgroup analysis indicated a significant racial difference with respect to CV benefit (P for interaction <0.001), and more substantial risk reductions were observed in subjects of African origin (relative risk [RR], 0.78; 95% CI, 0.60 to 0.99) and in Asians (RR, 0.35; 95% CI, 0.09 to 1.32). However, post hoc analysis (Bonferroni method) revealed that only Asians exhibited a significantly greater CV benefit from treatment, compared with white subjects (P<0.0001).

Conclusion

Long-acting GLP-1 RAs reduced risks of MACE and CV deaths in high-risk patients with type 2 diabetes mellitus. Our findings of a particularly effective reduction in CV events with GLP-1 RA in Asian populations merits further exploration and dedicated trials in specific populations.

Citations

Citations to this article as recorded by

Safety and Effectiveness of Dulaglutide in the Treatment of Type 2 Diabetes Mellitus: A Korean Real-World Post-Marketing Study
Jeonghee Han, Woo Je Lee, Kyu Yeon Hur, Jae Hyoung Cho, Byung Wan Lee, Cheol-Young Park
Diabetes & Metabolism Journal.2024; 48(3): 418. CrossRef
Sex, racial, ethnic, and geographical disparities in major adverse cardiovascular outcome of glucagon-like peptide-1 receptor agonists among patients with and without diabetes mellitus: A meta-analysis of placebo-controlled randomized controlled trials
Frederick Berro Rivera, Nathan Ross B. Bantayan, John Paul Aparece, Linnaeus Louisse A. Cruz, John Vincent Magallong, Polyn Luz Pine, Anne Mira Nicca Idian-Javier, Grace Nooriza O. Lumbang, Edgar V. Lerma, Kyla M. Lara-Breitinger, Martha Gulati, Krishnasw
Journal of Clinical Lipidology.2024; 18(4): e588. CrossRef
A randomized, double‐blind trial assessing the efficacy and safety of two doses of dulaglutide in Japanese participants with type 2 diabetes (AWARD‐JPN)
Tomoaki Morioka, Masakazu Takeuchi, Akichika Ozeki, Masanori Emoto
Diabetes, Obesity and Metabolism.2024; 26(8): 3167. CrossRef
Coronary Artery Disease in South Asian Patients: Cardiovascular Risk Factors, Pathogenesis and Treatments
Vincenzo Sucato, Giuseppe Coppola, Girolamo Manno, Giuseppe Vadalà, Giuseppina Novo, Egle Corrado, Alfredo Ruggero Galassi
Current Problems in Cardiology.2023; 48(8): 101228. CrossRef
Retrospective Analysis of the Effectiveness of Oral Semaglutide in Type 2 Diabetes Mellitus and Its Effect on Cardiometabolic Parameters in Japanese Clinical Settings
Hodaka Yamada, Masashi Yoshida, Shunsuke Funazaki, Jun Morimoto, Shiori Tonezawa, Asuka Takahashi, Shuichi Nagashima, Kimura Masahiko, Otsuka Kiyoshi, Kazuo Hara
Journal of Cardiovascular Development and Disease.2023; 10(4): 176. CrossRef
Efficacy of treatment with glucagon-like peptide receptor agonists-1 in Asian patients with type 2 diabetes mellitus
L. Yu. Khamnueva, L. S. Andreeva
Problems of Endocrinology.2023; 69(2): 38. CrossRef
Role of diabetes in stroke: Recent advances in pathophysiology and clinical management
Sian A. Bradley, Kevin J. Spring, Roy G. Beran, Dimitrios Chatzis, Murray C. Killingsworth, Sonu M. M. Bhaskar
Diabetes/Metabolism Research and Reviews.2022;[Epub] CrossRef
Obesity Pillars Roundtable: Obesity and East Asians
Harold Edward Bays, Jennifer Ng, Jeffrey Sicat, Michelle Look
Obesity Pillars.2022; 2: 100011. CrossRef
Pathophysiology, phenotypes and management of type 2 diabetes mellitus in Indian and Chinese populations
Calvin Ke, K. M. Venkat Narayan, Juliana C. N. Chan, Prabhat Jha, Baiju R. Shah
Nature Reviews Endocrinology.2022; 18(7): 413. CrossRef
Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
Timothy M. E. Davis, Anna Giczewska, Yuliya Lokhnygina, Robert J. Mentz, Naveed Sattar, Rury R. Holman
Cardiovascular Diabetology.2022;[Epub] CrossRef
Generalizability of the Results of Cardiovascular Outcome Trials of Glucagon-Like Peptide 1 Receptor Agonists in Chinese Patients with Type 2 Diabetes Mellitus
Xiaoling Cai, Linong Ji
Diabetes Therapy.2021; 12(7): 1861. CrossRef
Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes
Jae-Seung Yun, Seung-Hyun Ko
Metabolism.2021; 123: 154838. CrossRef
Sex and ethnic differences in the cardiovascular complications of type 2 diabetes
Jian L. Yeo, Emer M. Brady, Gerry P. McCann, Gaurav S. Gulsin
Therapeutic Advances in Endocrinology and Metabolism.2021; 12: 204201882110342. CrossRef
Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
Yuan Zhu, Jiao Xu, Dong Zhang, Xingyu Mu, Yi Shi, Shangtao Chen, Zengxiang Wu, Shuangqing Li
Frontiers in Endocrinology.2021;[Epub] CrossRef
Efficacy and safety of dulaglutide in type 2 diabetes patients in endocrinology clinics of Islamabad, Pakistan
Matiullah Kamin, SajjadAli Khan, UmarYousaf Raja, Osama Ishtiaq, Asmara Malik, Tejhmal Rehman, MuhammadUmar Wahab
Indian Journal of Endocrinology and Metabolism.2021; 25(5): 456. CrossRef
Type 2 Diabetes and Atherosclerotic Cardiovascular Disease in South Asians: a Unique Population with a Growing Challenge
Afreen I. Shariff, Nitya Kumar, William S. Yancy, Leonor Corsino
Current Diabetes Reports.2020;[Epub] CrossRef
Antihypertensive and Renal Mechanisms of SGLT2 (Sodium-Glucose Linked Transporter 2) Inhibitors
Christopher S. Wilcox
Hypertension.2020; 75(4): 894. CrossRef
Subpopulation Differences in the Cardiovascular Efficacy of Long-Acting Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis
Liyun He, Na Yang, Lingling Xu, Fan Ping, Wei Li, Yuxiu Li, Huabing Zhang
Diabetes Therapy.2020; 11(9): 2121. CrossRef
2020 Consensus of Taiwan Society of Cardiology on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases
Chern-En Chiang, Kwo-Chang Ueng, Ting-Hsing Chao, Tsung-Hsien Lin, Yih-Jer Wu, Kang-Ling Wang, Shih-Hsien Sung, Hung-I Yeh, Yi-Heng Li, Ping-Yen Liu, Kuan-Cheng Chang, Kou-Gi Shyu, Jin-Long Huang, Cheng-Dao Tsai, Huei-Fong Hung, Ming-En Liu, Tze-Fan Chao,
Journal of the Chinese Medical Association.2020; 83(7): 587. CrossRef
Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
Kyung-Soo Kim, Byung-Wan Lee
Clinical and Molecular Hepatology.2020; 26(4): 430. CrossRef

Review

Pathophysiology
Role of NO/VASP Signaling Pathway against Obesity-Related Inflammation and Insulin Resistance: Yu Mi Kang, Francis Kim, Woo Je Lee; Diabetes Metab J. 2017;41(2):89-95. Published online November 15, 2016; DOI: https://doi.org/10.4093/dmj.2017.41.2.89

5,111 View
74 Download
22 Web of Science
20 Crossref

Abstract PDF PubReader

Obesity has quickly become a worldwide pandemic, causing major adverse health outcomes such as dyslipidemia, type 2 diabetes mellitus, cardiovascular disease and cancers. Obesity-induced insulin resistance is the key for developing these metabolic disorders, and investigation to understand the molecular mechanisms involved has been vibrant for the past few decades. Of these, low-grade chronic inflammation is suggested as a critical concept in the development of obesity-induced insulin resistance, and the anti-inflammatory effect of nitric oxide (NO) signaling has been reported to be linked to improvement of insulin resistance in multiple organs involved in glucose metabolism. Recently, a body of evidence suggested that vasodilatory-stimulated phosphoprotein (VASP), a downstream mediator of NO signaling plays a crucial role in the anti-inflammatory effect and improvement of peripheral insulin resistance. These preclinical studies suggest that NO/VASP signaling could be an ideal therapeutic target in the treatment of obesity-related metabolic dysfunction. In this review, we introduce studies that investigated the protective role of NO/VASP signaling against obesity-related inflammation and insulin resistance in various tissues.

Citations

Citations to this article as recorded by

Hippocampal proteomic changes in high-fat diet-induced obese mice associated with memory decline
Ping Lu, Cun-Xiu Gao, Fei-Jian Luo, Yu-Ting Huang, Mei-Mei Gao, Yue-Sheng Long
The Journal of Nutritional Biochemistry.2024; 125: 109554. CrossRef
Gases and gas-releasing materials for the treatment of chronic diabetic wounds
Shuming Ye, Neng Jin, Nan Liu, Feixiang Cheng, Liang Hu, Guiyang Zhang, Qi Li, Juehua Jing
Biomaterials Science.2024; 12(13): 3273. CrossRef
Leptina, obesidad y enfermedades cardiovasculares
Jorly Mejia-Montilla , Nadia Reyna-Villasmil, Andreina Fernández-Ramírez, Eduardo Reyna-Villasmil
Revista Repertorio de Medicina y Cirugía.2023; 32(3): 218. CrossRef
Urinary and circulatory netrin-1 as biomarker in diabetes and its related complications: a systematic review and meta-analysis
Amir Hossein Behnoush, Amirmohammad Khalaji, Zahra Shokri Varniab, Afshin Rahbarghazi, Elahe Amini, Aleksandra Klisic
Endocrine.2023; 84(2): 328. CrossRef
Impact of ultraviolet radiation on cardiovascular and metabolic disorders: The role of nitric oxide and vitamin D
Qing‐Ling Quan, Kyeong‐No Yoon, Ji Su Lee, Eun Ju Kim, Dong Hun Lee
Photodermatology, Photoimmunology & Photomedicine.2023; 39(6): 573. CrossRef
Beneficial Metabolic Effects of Praliciguat, a Soluble Guanylate Cyclase Stimulator, in a Mouse Diet-Induced Obesity Model
Chad D. Schwartzkopf, John R. Hadcock, Guang Liu, Peter Germano, Julien Roux, Courtney M. Shea, Emmanuel S. Buys, Juli E. Jones
Frontiers in Pharmacology.2022;[Epub] CrossRef
Type 2 Diabetes Complicated With Heart Failure: Research on Therapeutic Mechanism and Potential Drug Development Based on Insulin Signaling Pathway
Hui Ye, Yanan He, Chuan Zheng, Fang Wang, Ming Yang, Junzhi Lin, Runchun Xu, Dingkun Zhang
Frontiers in Pharmacology.2022;[Epub] CrossRef
Effect of low-dose tadalafil once daily on glycemic control in patients with type 2 diabetes and erectile dysfunction: a randomized, double-blind, placebo-controlled pilot study
Min-Kyung Lee, Jae-Hyuk Lee, Seo-Young Sohn, Seo Yeon Lee, Tae-Yoong Jeong, Sae Chul Kim
Diabetology & Metabolic Syndrome.2022;[Epub] CrossRef
In situ hydrogel capturing nitric oxide microbubbles accelerates the healing of diabetic foot
Yingzheng Zhao, Lanzi Luo, Lantian Huang, Yingying Zhang, Mengqi Tong, Hanxiao Pan, Jianxun Shangguan, Qing Yao, Shihao Xu, Helin Xu
Journal of Controlled Release.2022; 350: 93. CrossRef
Amelioration effect of black seed oil against high‐fat diet‐induced obesity in rats through Nrf2/HO‐1 pathway
Nada F. Abo El‐Magd, Mohamed El‐Mesery, Amro El‐Karef, Mamdouh M. El‐Shishtawy
Journal of Food Biochemistry.2021;[Epub] CrossRef
An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension
John P. Hanrahan, Jelena P. Seferovic, James D. Wakefield, Phebe J. Wilson, Jennifer G. Chickering, Joon Jung, Kenneth E. Carlson, Daniel P. Zimmer, Andrew L. Frelinger, Alan D. Michelson, Linda Morrow, Michael Hall, Mark G. Currie, G. Todd Milne, Albert
Diabetologia.2020; 63(4): 733. CrossRef
Advantages of Phosphodiesterase Type 5 Inhibitors in the Management of Glucose Metabolism Disorders: A Clinical and Translational Issue
Cristina Antinozzi, Paolo Sgrò, Luigi Di Luigi
International Journal of Endocrinology.2020; 2020: 1. CrossRef
Association of endothelial dysfunction with incident prediabetes, type 2 diabetes and related traits: the KORA F4/FF4 study
Marie-Theres Huemer, Cornelia Huth, Florian Schederecker, Stefanie J Klug, Christa Meisinger, Wolfgang Koenig, Wolfgang Rathmann, Annette Peters, Barbara Thorand
BMJ Open Diabetes Research & Care.2020; 8(1): e001321. CrossRef
Embelin fromEmbelia ribesameliorates oxidative stress and inflammation in high-fat diet-fed obese C57BL/6 mice
Priyanka Bansal, Uma Bhandari, Sayeed Ahmad
Pharmacognosy Magazine.2020; 16(5): 443. CrossRef
Weight change is significantly associated with risk of thyroid cancer: A nationwide population-based cohort study
Hyemi Kwon, Kyung-Do Han, Cheol-Young Park
Scientific Reports.2019;[Epub] CrossRef
Diabetes and Cancer: Cancer Should Be Screened in Routine Diabetes Assessment
Sunghwan Suh, Kwang-Won Kim
Diabetes & Metabolism Journal.2019; 43(6): 733. CrossRef
Antioxidant, antihyperglycemic, and antidiabetic activity of Apis mellifera bee tea
Janielle da Silva Melo da Cunha, Tamaeh Monteiro Alfredo, Jéssica Maurino dos Santos, Valter Vieira Alves Junior, Luiza Antas Rabelo, Emerson Silva Lima, Ana Paula de Araújo Boleti, Carlos Alexandre Carollo, Edson Lucas dos Santos, Kely de Picoli Souza, M
PLOS ONE.2018; 13(6): e0197071. CrossRef
Relationship Between Circulating Netrin-1 Concentration, Impaired Fasting Glucose, and Newly Diagnosed Type 2 Diabetes
Jisook Yim, Gyuri Kim, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Jeong-Ho Kim, Jin Won Cho, Sang-Guk Lee, Yong-ho Lee
Frontiers in Endocrinology.2018;[Epub] CrossRef
Glycyrrhizin ameliorates high fat diet-induced obesity in rats by activating NrF2 pathway
Nada F. Abo El-Magd, Mohamed El-Mesery, Amro El-Karef, Mamdouh M. El-Shishtawy
Life Sciences.2018; 193: 159. CrossRef
cGMP-dependent protein kinase I (cGKI) modulates human hepatic stellate cell activation
Andras Franko, Marketa Kovarova, Susanne Feil, Robert Feil, Robert Wagner, Martin Heni, Alfred Königsrainer, Marc Ruoß, Andreas K. Nüssler, Cora Weigert, Hans-Ulrich Häring, Stefan Z. Lutz, Andreas Peter
Metabolism.2018; 88: 22. CrossRef

Original Article

Serum Ceruloplasmin Level as a Predictor for the Progression of Diabetic Nephropathy in Korean Men with Type 2 Diabetes Mellitus: Min Jung Lee, Chang Hee Jung, Yu Mi Kang, Jung Eun Jang, Jaechan Leem, Joong-Yeol Park, Woo Je Lee; Diabetes Metab J. 2015;39(3):230-239. Published online April 22, 2015; DOI: https://doi.org/10.4093/dmj.2015.39.3.230

5,143 View
55 Download
24 Web of Science
25 Crossref

Abstract PDF PubReader

Background

Oxidative stress is known to be associated with progression of diabetic kidney disease. Ceruloplasmin acts as a pro-oxidant under conditions of severe oxidative stress. Thus, we conducted a longitudinal observational study to evaluate whether the serum ceruloplasmin level is a predictive biomarker for progression of diabetic nephropathy.

Methods

A total of 643 Korean men with type 2 diabetes mellitus were enrolled. Serum ceruloplasmin was measured using a nephelometric method. Progression of diabetic nephropathy was defined as transition in albuminuria class (i.e., normoalbuminuria to microalbuminuria, microalbuminuria to macroalbuminuria, or normoalbuminuria to macroalbuminuria) and/or a greater than 2-fold increase of serum creatinine at follow-up compared with the baseline value.

Results

During the follow-up period (median, 2.7 years; range, 0.3 to 4.4 years), 49 of 643 patients (7.6%) showed the progression of diabetic nephropathy and three patients (0.5%) developed end-stage renal disease. Baseline ceruloplasmin levels were higher in the progressors than in the nonprogressors (262.6±40.9 mg/L vs. 233.3±37.8 mg/L, P<0.001). Kaplan-Meier analysis showed a significantly higher incidence of nephropathy progression according to ceruloplasmin tertile (log-rank test, P<0.001). The hazard ratio (HR) for progression of diabetic nephropathy was significantly higher in the highest ceruloplasmin tertile category compared with the lowest ceruloplasmin tertile category, even after adjusting for confounding variables (HR, 3.32; 95% confidence interval, 1.28 to 8.61; P=0.003).

Conclusion

Baseline serum ceruloplasmin is an independent predictive factor for the progression of diabetic nephropathy in patients with type 2 diabetes mellitus.

Citations

Citations to this article as recorded by

Proteomic analysis of urinary exosomes reveals ferroptosis-associated proteins are involved in diabetic nephropathy
Kaida Mu, Yanping Yang, Xiaofei An, Jie Zhu, Jing Zhang, Yanfei Jiang, Xiaorong Yang, Jinan Zhang
Genes & Diseases.2024; 11(5): 101138. CrossRef
Modulatory role of Annona squamosa extract against streptozotocin-induced diabetic nephropathy in male rats
Ghaliah Almalki, Norah Alothman, Gamal Mohamed, Mohammed Akeel, Abd El-Fattah B.M. El-Beltagy, Eman T. Salem
Egyptian Journal of Basic and Applied Sciences.2024; 11(1): 536. CrossRef
WITHDRAWN: Research on Traditional Chinese Medicine Syndrome Animal Models and Multi-omics Biomarkers in Type II Diabetes: A Review
Yifei Wang, Yan Gao, Bonian Zhao
Pharmacological Research - Modern Chinese Medicine.2024; : 100471. CrossRef
In-depth urinary and exosome proteome profiling analysis identifies novel biomarkers for diabetic kidney disease
Shichun Du, Linhui Zhai, Shu Ye, Le Wang, Muyin Liu, Minjia Tan
Science China Life Sciences.2023; 66(11): 2587. CrossRef
Serum Level of Ceruloplasmin, Angiotensin-Converting Enzyme and Transferrin as Markers of Severity in SARS-CoV-2 Infection in Patients with Type 2 Diabetes
Patricia-Andrada Reștea, Ștefan Țigan, Laura Grațiela Vicaș, Luminița Fritea, Eleonora Marian, Tunde Jurca, Annamaria Pallag, Iulius Liviu Mureșan, Corina Moisa, Otilia Micle, Mariana Eugenia Mureșan
Microbiology Research.2023; 14(4): 1670. CrossRef
The nephropathy of sickle cell trait and sickle cell disease
Kenneth I. Ataga, Santosh L. Saraf, Vimal K. Derebail
Nature Reviews Nephrology.2022; 18(6): 361. CrossRef
Integrated Analysis of Single-Cell RNA-seq and Bulk RNA-seq in the Identification of a Novel ceRNA Network and Key Biomarkers in Diabetic Kidney Disease
Yuejun Wang, Mingming Zhao, Yu Zhang
International Journal of General Medicine.2022; Volume 15: 1985. CrossRef
Molecular Functions of Ceruloplasmin in Metabolic Disease Pathology
Zhidong Liu, Miao Wang, Chunbo Zhang, Shigao Zhou, Guang Ji
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2022; Volume 15: 695. CrossRef
A correlative study of copper, ceruloplasmin, iron, total iron binding capacity and total antioxidant capacity in diabetic nephropathy
Ramlingareddy, Shivashankara A Ramachandrayya, Jeena Jacob, Malathi Mala
Biomedicine.2022; 42(3): 469. CrossRef
Novel biomarkers for prognosticating diabetic kidney disease progression
Shilna Muttickal Swaminathan, Indu Ramachandra Rao, Srinivas Vinayak Shenoy, Attur Ravindra Prabhu, Pooja Basthi Mohan, Dharshan Rangaswamy, Mohan V Bhojaraja, Shivashankara Kaniyoor Nagri, Shankar Prasad Nagaraju
International Urology and Nephrology.2022; 55(4): 913. CrossRef
Evaluation of Serum Ceruloplasmin Levels as a Biomarker for Oxidative Stress in Patients With Diabetic Retinopathy
Gurunadh Satyanarayana, Narendra Keisham, Hitender S Batra, Subrahmanya Murti V, Mansur Khan, Sandeep Gupta, Vikram Mahindra
Cureus.2021;[Epub] CrossRef
Prospection of plasma proteins as biomarkers for diabetes mellitus monitoring
Liliane de Paula Silva, Fabiane Gomes de Moraes Rego, Geraldo Picheth, Marcelo Müller-Santos, Dayane Alberton
Journal of Diabetes & Metabolic Disorders.2021; 20(1): 611. CrossRef
Risk assessment for foot ulcers among Tunisian subjects with diabetes: a cross sectional outpatient study
B. Zantour, S. Bouchareb, Z. El Ati, F. Boubaker, W. Alaya, W. Kossomtini, M. H. Sfar
BMC Endocrine Disorders.2020;[Epub] CrossRef
Metalloproteins and apolipoprotein C: candidate plasma biomarkers of T2DM screened by comparative proteomics and lipidomics in ZDF rats
Shuai Wang, Zhiyuan Lu, Yuxin Wang, Tianran Zhang, Xiaodong He
Nutrition & Metabolism.2020;[Epub] CrossRef
Emerging vistas on electrochemical detection of diabetic retinopathy biomarkers
K.S. Shalini Devi, Madhurantakam Sasya, Uma Maheswari Krishnan
TrAC Trends in Analytical Chemistry.2020; 125: 115838. CrossRef
Oxidative stress in peritoneal dialysis patients: Association with the dialysis adequacy and technique survival
Natalia Stepanova, Lesya Korol, Olena Burdeyna
Indian Journal of Nephrology.2019; 29(5): 309. CrossRef
Recent advancements in biopolymer and metal nanoparticle-based materials in diabetic wound healing management
Veena Vijayakumar, Sushanta K. Samal, Smita Mohanty, Sanjay K. Nayak
International Journal of Biological Macromolecules.2019; 122: 137. CrossRef
Rat Böbrek Dokusunda Kurşunun Neden Olduğu Oksidatif Strese Karşı Kitosanın Koruyucu etkisi
Ugur ÖZDEK, Hasan TOZ, Ahmet Ufuk KÖMÜROĞLU, Leyla MİS, Zübeyir HUYUT, Yeter DEĞER
Van Veterinary Journal.2019; 30(3): 187. CrossRef
Changes in Trace Elements During Early Stages of Chronic Kidney Disease in Type 2 Diabetic Patients
Ching-Chiang Lin, Ching-Tang Shih, Chien-Hung Lee, Yeou-Lih Huang
Biological Trace Element Research.2018; 186(2): 330. CrossRef
The Divalent Elements Changes in Early Stages of Chronic Kidney Disease
Wan-Ju Kung, Ching-Tang Shih, Chien-Hung Lee, Ching-Chiang Lin
Biological Trace Element Research.2018; 185(1): 30. CrossRef
Long-term expression of glomerular genes in diabetic nephropathy
Dominik Chittka, Bernhard Banas, Laura Lennartz, Franz Josef Putz, Kathrin Eidenschink, Sebastian Beck, Thomas Stempfl, Christoph Moehle, Simone Reichelt-Wurm, Miriam C Banas
Nephrology Dialysis Transplantation.2018;[Epub] CrossRef
Incidence of chronic kidney disease among people with diabetes: a systematic review of observational studies
D. N. Koye, J. E. Shaw, C. M. Reid, R. C. Atkins, A. T. Reutens, D. J. Magliano
Diabetic Medicine.2017; 34(7): 887. CrossRef
Global epidemiology of diabetic foot ulceration: a systematic review and meta-analysis
Pengzi Zhang, Jing Lu, Yali Jing, Sunyinyan Tang, Dalong Zhu, Yan Bi
Annals of Medicine.2017; 49(2): 106. CrossRef
Biomarkers of diabetic nephropathy: A 2017 update
Nektaria Papadopoulou-Marketou, Christina Kanaka-Gantenbein, Nikolaos Marketos, George P. Chrousos, Ioannis Papassotiriou
Critical Reviews in Clinical Laboratory Sciences.2017; 54(5): 326. CrossRef
Serum Vascular Adhesion Protein-1 Predicts End-Stage Renal Disease in Patients with Type 2 Diabetes
Hung-Yuan Li, Hung-An Lin, Feng-Jung Nien, Vin-Cent Wu, Yi-Der Jiang, Tien-Jyun Chang, Hsien-Li Kao, Mao-Shin Lin, Jung-Nan Wei, Cheng-Hsin Lin, Shyang-Rong Shih, Chi-Sheng Hung, Lee-Ming Chuang, Emmanuel A Burdmann
PLOS ONE.2016; 11(2): e0147981. CrossRef

First
Prev
Page of 1
Next
Last

Search